Pharmacogenomics Market Size 2025-2029
The pharmacogenomics market size is forecast to increase by USD 2.5 billion, at a CAGR of 6.5% between 2024 and 2029.
The global pharmacogenomics market is driven by the imperative of personalized medicine, which tailors drug therapies based on an individual's genetic makeup to improve outcomes. This approach involves extensive genetic variant analysis and drug response profiling. A key trend is the integration of artificial intelligence, which enhances the precision of genomic data interpretation and biomarker discovery services. This convergence of genomics and AI is crucial for advancing the molecular diagnostics market. However, the market's progress is constrained by inconsistent reimbursement policies and the challenge of demonstrating the cost-effectiveness of pharmacogenomic tests, which can create financial barriers to wider adoption and limit the full potential of personalized therapeutic drug monitoring.Advancements in the bio-pharma sector are closely tied to the evolution of pharmacogenomics, with a focus on gene-drug interaction analysis to minimize adverse reactions. The use of sophisticated tools for multi-omics data integration allows for a more holistic view of patient health, supporting better clinical decision support tools. This aligns with trends in the broader next generation sequencing market, where data analysis capabilities are critical. The development of targeted therapy and patient stratification methods are becoming standard in areas like oncology, supported by ongoing research into drug efficacy prediction. Addressing reimbursement issues is essential for translating these technological advancements into standard clinical practice globally.
What will be the Size of the Pharmacogenomics Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
Market dynamics are continuously shaped by advancements in drug response profiling and biomarker discovery services. The emphasis is on refining molecular diagnostic assays to achieve greater precision in therapy selection. This evolution within the broader molecular diagnostics market is steering development toward more integrated approaches that combine genetic data with other clinical information.The ongoing integration of multi-omics data is becoming central to understanding complex gene-drug interactions. This process requires sophisticated genomic data interpretation and real-world data analysis to validate findings across diverse populations. Developments in proteomics and metabolomics are contributing to a more comprehensive framework for predicting treatment outcomes.
How is this Pharmacogenomics Industry segmented?
The pharmacogenomics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- End-user
- Hospitals and clinics
- Research organizations
- Academic
- Application
- Oncology
- Drug discovery
- Pain management
- Neurology
- Others
- Technology
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Asia
- Rest of World (ROW)
By End-user Insights
The hospitals and clinics segment is estimated to witness significant growth during the forecast period.
Hospitals and clinics are a rapidly expanding end-user segment, driven by the increasing adoption of pharmacogenomic testing to personalize drug therapy. This adoption is aimed at improving efficacy and reducing adverse drug reactions. A retrospective analysis highlighted this trend, revealing a 35 percent growth in test volume over a one-year period in a hospital setting. The implementation of preemptive pharmacogenomics programs, which integrate genetic data into electronic health records, exemplifies this shift toward embedding genomic insights into routine care.
The growth in this segment is further supported by national initiatives and the availability of clinical guidelines that provide evidence-based information for prescribing decisions. The development of clinical decision support tools helps healthcare professionals apply genetic test results confidently. The primary objective is to transition from a one-size-fits-all medical approach to a more precise, individualized strategy. This focus on medicines optimization is expected to accelerate the adoption of pharmacogenomic testing within clinical workflows and primary care.
Request Free Sample
The Hospitals and clinics segment was valued at USD 3.2 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 39.2% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
North America is the dominant region in the global pharmacogenomics market, distinguished by its sophisticated healthcare infrastructure and early adoption of precision medicine. The region's leadership is reinforced by substantial healthcare expenditure and a supportive regulatory environment that promotes innovation in genomic medicine integration. The high prevalence of chronic diseases further drives demand for tailored therapies. A key trend is the increasing incorporation of pharmacogenomic biomarkers into clinical trials, which accelerates companion diagnostic development and market expansion.
The United States commands the largest portion of the North America market, fueled by robust government initiatives and high awareness among providers. North America is poised to contribute 39.2% of the total market growth, underscoring its pivotal role in the industry's future. The presence of major pharmaceutical companies and leading academic institutions creates a synergistic ecosystem that facilitates the clinical integration of pharmacogenomic testing. This dynamic environment solidifies the region's position as the primary hub for innovation and commercial activity in the market.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global pharmacogenomics market is rapidly expanding, driven by the push for pharmacogenomic strategies for personalized drug treatments. Key industry focus includes advancing genomic sequencing with new partnerships and improving access to oncology testing globally. Companies are heavily invested in biomarker discovery for personalized therapeutic development and developing next-generation precision oncology treatments. A significant trend is the application of machine learning for oncological pharmacogenomics analysis, which complements the growing use of artificial intelligence in immuno-oncology treatment strategies. Furthermore, the successful clinical implementation of pharmacogenetics in primary care and the crucial task of integrating pharmacogenomic data into electronic health records are paving the way for widespread adoption. Evaluating the cost-effectiveness of pharmacogenomic guided therapy is essential for market penetration.To achieve these goals, stakeholders are focused on developing companion diagnostics for targeted cancer therapies and utilizing preemptive pharmacogenomics for clinical decision support. The validation of these approaches often involves using real-world data for pharmacogenomic validation. On the technical front, innovations like using digital PCR for rare allele detection are critical, alongside established methods such as using TaqMan assays for high-throughput genotyping. Core diagnostic services include genetic testing for CYP450 and other drug-metabolizing genes and specific applications like pharmacogenomic testing for major depressive disorder. The field is increasingly reliant on analyzing multi-omics data with machine learning models. This entire ecosystem of biomarker-based genetic testing for precision medicine hinges on overcoming hurdles like standardizing reimbursement for pharmacogenomic tests to ensure equitable access and sustained growth.
What are the key market drivers leading to the rise in the adoption of Pharmacogenomics Industry?
- The critical need to adopt personalized medicine is the foremost driver shaping the pharmacogenomics market.
The paradigm shift toward personalized medicine is a primary driver, fundamentally altering healthcare by tailoring treatments to individual genetic profiles. This approach moves beyond a one-size-fits-all model to optimize drug efficacy and minimize adverse reactions through detailed drug response profiling and genetic variant analysis. The growing recognition of genetics' role in therapeutic outcomes is prompting wider adoption of molecular diagnostic assays. The commitment to this tailored strategy is evident as personalized medicines now account for over 33% of new drug approvals, indicating strong regulatory and commercial momentum toward therapies guided by genetic insights and biomarker discovery services.The escalating burden of chronic diseases worldwide creates a sustained demand for more precise and effective treatments, which pharmacogenomics helps to address. Conditions requiring long-term management benefit significantly from patient stratification methods that identify individuals most likely to respond to a specific therapy. With approximately 25% of the population in major economies being physically inactive, lifestyle-related chronic illnesses are rising, intensifying the need for targeted therapy development. This driver is directly linked to the need for adverse drug reaction reduction and improved therapeutic outcomes, making drug efficacy prediction a critical area of focus for healthcare systems globally.
What are the market trends shaping the Pharmacogenomics Industry?
- The integration of artificial intelligence and machine learning is a pivotal upcoming trend transforming the pharmacogenomics landscape.
The integration of artificial intelligence and machine learning is a pivotal trend, enhancing the precision of personalized medicine by analyzing complex genomic datasets. This convergence, central to the drug discovery informatics market, enables the identification of novel gene-drug interactions and more accurate predictions of patient responses. For instance, some analyses have shown a 35% growth rate in test volume over a one-year period after clinical implementation, with oncology being a primary user. AI-driven multi-omics data integration provides a holistic understanding of how genomic variants influence therapeutic outcomes, moving beyond single-gene analyses. These advanced bioinformatics techniques are reshaping drug discovery by improving patient stratification methods for clinical trials and accelerating development timelines.An evolving regulatory landscape and increased clinical implementation are shaping market dynamics, fostering greater adoption of pharmacogenomic testing. As part of the broader genomics field, regulatory bodies are establishing clearer guidelines for the validation and use of genetic biomarker validation, which builds confidence among clinicians and payers. This trend is complemented by the work of consortia that provide evidence-based prescribing guidelines, translating genetic test results into actionable clinical decisions. With nearly a quarter of the population in some developed nations projected to be over 60, the need for safer medication management through pharmacokinetics services is becoming more acute, further driving the integration of these regulated tests into standard care.
What challenges does the Pharmacogenomics Industry face during its growth?
- Inconsistent reimbursement policies and the difficulty in demonstrating cost-effectiveness represent a primary challenge for the pharmacogenomics market.
A primary challenge is the inconsistent reimbursement landscape and the need to demonstrate cost-effectiveness. Payers often require extensive evidence of clinical utility before covering pharmacogenomic tests, creating financial barriers. The difficulty in conducting long-term studies to prove economic value, such as reduced hospitalizations, slows integration into standard care. With one key region projected to contribute nearly 40% of the market's incremental growth, overcoming these access barriers is critical for realizing the market's potential. This situation creates uncertainty for providers and can limit patient access, even as technologies for drug metabolism analysis and adverse drug reaction reduction become more advanced.Clinical implementation, education, and standardization present another significant hurdle. The successful integration of pharmacogenomics into routine care depends on the availability of healthcare professionals skilled in genomic data interpretation and its application. A lack of standardized protocols and clinical decision support tools can lead to variability in practice and hinder adoption. The high impact of undifferentiated purchases on buyer dynamics underscores the need for clear value propositions that go beyond the technology itself, focusing instead on improved patient outcomes. This challenge highlights the gap between technological capability, such as advanced genotyping assay development, and its practical application in diverse healthcare settings.
Exclusive Customer Landscape
The pharmacogenomics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the pharmacogenomics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, pharmacogenomics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Abbott Laboratories - Offerings in this market encompass molecular diagnostic assays and genetic testing centered on biomarkers. These solutions are pivotal for enabling precision drug selection and facilitating personalized therapy monitoring, aligning with the broader shift toward tailored medical treatments.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Abbott Laboratories
- Admera Health
- Agilent Technologies Inc.
- Bayer AG
- Bio Rad Laboratories Inc.
- Charles River Laboratories International Inc.
- Danaher Corp.
- Eurofins Scientific SE
- F. Hoffmann La Roche Ltd.
- GE Healthcare Technologies Inc.
- geneOmbio Technologies Pvt. Ltd.
- Illumina Inc.
- Laboratory Corp. of America Holdings
- Merck and Co. Inc.
- Myriad Genetics Inc.
- OneOme LLC
- QIAGEN N.V.
- Regeneron Pharmaceuticals Inc.
- Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Pharmacogenomics Market
In March 2024, Bayer AG expanded its partnership with Thermo Fisher Scientific Inc. to develop companion diagnostic tests for its growing portfolio of precision cancer therapies.In March 2024, Bayer AG collaborated with Aignostics GmbH to leverage AI-powered pathology for developing next-generation precision oncology treatments.In February 2024, QIAGEN N.V. launched its QIAseq Targeted DNA Pro Panels for biomarker discovery, enhancing research in areas like immuno-oncology and inherited diseases.In January 2024, Illumina Inc. announced a new co-development partnership with Janssen Research & Development to create a novel molecular residual disease assay for cancer treatment.In January 2024, Danaher Corp. partnered with the Innovative Genomics Institute to launch the Danaher-IGI Beacon for CRISPR Cures, an initiative to accelerate the development of gene-editing therapies.
Research Analyst Overview
The global pharmacogenomics market is characterized by the continuous refinement of core analytical techniques and their expanding applications. The evolution of genetic variant analysis, encompassing single nucleotide polymorphisms and copy number variation analysis, is fundamental to improving drug response profiling and drug efficacy prediction. This progress supports biomarker discovery services and informs both genotyping assay development and the validation of genetic biomarkers. The application of next-generation sequencing testing, dependent on genomic sequencing reagents, enhances drug metabolism analysis and CYP450 gene testing. These advancements are vital for improving cancer patient diagnostics and oncology testing access, with automated test systems facilitating wider integration and preclinical genomic analysis supporting early-stage research.The clinical implementation of these technologies focuses on personalized medicine implementation and evidence-based prescribing. Pharmacogenetic testing programs are integral to a medicines optimization strategy, aiming for precision drug selection and significant adverse drug reaction reduction. The integration of clinical decision support tools is crucial for effective genomic data interpretation and multi-omics data integration, especially in managing conditions like treatment-resistant depression and major depressive disorder. With the market anticipated to expand by nearly 8% in the coming fiscal period, health technology assessment and real-world data analysis are essential for building clinical utility evidence, guiding companion diagnostic development, and refining patient stratification methods for clinical trial patient stratification.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Pharmacogenomics Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
308
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 6.5%
|
|
Market growth 2024-2029
|
USD 2.5 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
6.0%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, Sweden, China, Japan, India, South Korea, Singapore, Taiwan, Indonesia, Brazil, South Africa, Saudi Arabia, UAE, Argentina, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Pharmacogenomics Market Research and Growth Report?
- CAGR of the Pharmacogenomics industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the pharmacogenomics market growth of industry companies
We can help! Our analysts can customize this pharmacogenomics market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Pharmacogenomics Market 2019 - 2023
- Historic Market Size - Data Table on Global Pharmacogenomics Market 2019 - 2023 ($ billion)
- 5.2 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ billion)
- 5.3 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.4 Technology segment analysis 2019 - 2023
- Historic Market Size - Technology Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 Impact of AI on Global Pharmacogenomics Market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by End-user
- 8 Market Segmentation by End-user
- 8.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 8.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 8.3 Hospitals and clinics - Market size and forecast 2024-2029
- Chart on Hospitals and clinics - Market size and forecast 2024-2029 ($ billion)
- Data Table on Hospitals and clinics - Market size and forecast 2024-2029 ($ billion)
- Chart on Hospitals and clinics - Year-over-year growth 2024-2029 (%)
- Data Table on Hospitals and clinics - Year-over-year growth 2024-2029 (%)
- 8.4 Research organizations - Market size and forecast 2024-2029
- Chart on Research organizations - Market size and forecast 2024-2029 ($ billion)
- Data Table on Research organizations - Market size and forecast 2024-2029 ($ billion)
- Chart on Research organizations - Year-over-year growth 2024-2029 (%)
- Data Table on Research organizations - Year-over-year growth 2024-2029 (%)
- 8.5 Academic - Market size and forecast 2024-2029
- Chart on Academic - Market size and forecast 2024-2029 ($ billion)
- Data Table on Academic - Market size and forecast 2024-2029 ($ billion)
- Chart on Academic - Year-over-year growth 2024-2029 (%)
- Data Table on Academic - Year-over-year growth 2024-2029 (%)
- 8.6 Market opportunity by End-user
- Market opportunity by End-user ($ billion)
- Data Table on Market opportunity by End-user ($ billion)
9 Market Segmentation by Application
- 9 Market Segmentation by Application
- 9.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 9.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 9.3 Oncology - Market size and forecast 2024-2029
- Chart on Oncology - Market size and forecast 2024-2029 ($ billion)
- Data Table on Oncology - Market size and forecast 2024-2029 ($ billion)
- Chart on Oncology - Year-over-year growth 2024-2029 (%)
- Data Table on Oncology - Year-over-year growth 2024-2029 (%)
- 9.4 Drug discovery - Market size and forecast 2024-2029
- Chart on Drug discovery - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug discovery - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug discovery - Year-over-year growth 2024-2029 (%)
- Data Table on Drug discovery - Year-over-year growth 2024-2029 (%)
- 9.5 Pain management - Market size and forecast 2024-2029
- Chart on Pain management - Market size and forecast 2024-2029 ($ billion)
- Data Table on Pain management - Market size and forecast 2024-2029 ($ billion)
- Chart on Pain management - Year-over-year growth 2024-2029 (%)
- Data Table on Pain management - Year-over-year growth 2024-2029 (%)
- 9.6 Neurology - Market size and forecast 2024-2029
- Chart on Neurology - Market size and forecast 2024-2029 ($ billion)
- Data Table on Neurology - Market size and forecast 2024-2029 ($ billion)
- Chart on Neurology - Year-over-year growth 2024-2029 (%)
- Data Table on Neurology - Year-over-year growth 2024-2029 (%)
- 9.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 9.8 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
10 Market Segmentation by Technology
- 10 Market Segmentation by Technology
- 10.1 Market segments
- Chart on Technology - Market share 2024-2029 (%)
- Data Table on Technology - Market share 2024-2029 (%)
- 10.2 Comparison by Technology
- Chart on Comparison by Technology
- Data Table on Comparison by Technology
- 10.3 Polymerase chain reaction - Market size and forecast 2024-2029
- Chart on Polymerase chain reaction - Market size and forecast 2024-2029 ($ billion)
- Data Table on Polymerase chain reaction - Market size and forecast 2024-2029 ($ billion)
- Chart on Polymerase chain reaction - Year-over-year growth 2024-2029 (%)
- Data Table on Polymerase chain reaction - Year-over-year growth 2024-2029 (%)
- 10.4 DNA sequencing - Market size and forecast 2024-2029
- Chart on DNA sequencing - Market size and forecast 2024-2029 ($ billion)
- Data Table on DNA sequencing - Market size and forecast 2024-2029 ($ billion)
- Chart on DNA sequencing - Year-over-year growth 2024-2029 (%)
- Data Table on DNA sequencing - Year-over-year growth 2024-2029 (%)
- 10.5 Mass spectrometry - Market size and forecast 2024-2029
- Chart on Mass spectrometry - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mass spectrometry - Market size and forecast 2024-2029 ($ billion)
- Chart on Mass spectrometry - Year-over-year growth 2024-2029 (%)
- Data Table on Mass spectrometry - Year-over-year growth 2024-2029 (%)
- 10.6 Microarray - Market size and forecast 2024-2029
- Chart on Microarray - Market size and forecast 2024-2029 ($ billion)
- Data Table on Microarray - Market size and forecast 2024-2029 ($ billion)
- Chart on Microarray - Year-over-year growth 2024-2029 (%)
- Data Table on Microarray - Year-over-year growth 2024-2029 (%)
- 10.7 Electrophoresis - Market size and forecast 2024-2029
- Chart on Electrophoresis - Market size and forecast 2024-2029 ($ billion)
- Data Table on Electrophoresis - Market size and forecast 2024-2029 ($ billion)
- Chart on Electrophoresis - Year-over-year growth 2024-2029 (%)
- Data Table on Electrophoresis - Year-over-year growth 2024-2029 (%)
- 10.8 Market opportunity by Technology
- Market opportunity by Technology ($ billion)
- Data Table on Market opportunity by Technology ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.4.6 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.4.7 Sweden - Market size and forecast 2024-2029
- Chart on Sweden - Market size and forecast 2024-2029 ($ billion)
- Data Table on Sweden - Market size and forecast 2024-2029 ($ billion)
- Chart on Sweden - Year-over-year growth 2024-2029 (%)
- Data Table on Sweden - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 12.5.6 Taiwan - Market size and forecast 2024-2029
- Chart on Taiwan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Taiwan - Market size and forecast 2024-2029 ($ billion)
- Chart on Taiwan - Year-over-year growth 2024-2029 (%)
- Data Table on Taiwan - Year-over-year growth 2024-2029 (%)
- 12.5.7 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.3 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.4 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.5 Argentina - Market size and forecast 2024-2029
- Chart on Argentina - Market size and forecast 2024-2029 ($ billion)
- Data Table on Argentina - Market size and forecast 2024-2029 ($ billion)
- Chart on Argentina - Year-over-year growth 2024-2029 (%)
- Data Table on Argentina - Year-over-year growth 2024-2029 (%)
- 12.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Imperative of personalized medicine
- Escalating burden of chronic diseases
- Accelerating technological advancements in genomics and bioinformatics
- 13.2 Market challenges
- Reimbursement and demonstration of cost-effectiveness
- Clinical implementation, education, and standardization
- Ethical, legal, and social issues including regulatory oversight and data privacy
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Integration of artificial intelligence and machine learning
- Evolving regulatory landscape and increased clinical implementation
- Strategic partnerships and expansion into new therapeutic areas
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Abbott Laboratories
- Abbott Laboratories - Overview
- Abbott Laboratories - Business segments
- Abbott Laboratories - Key news
- Abbott Laboratories - Key offerings
- Abbott Laboratories - Segment focus
- SWOT
- 15.5 Admera Health
- Admera Health - Overview
- Admera Health - Product / Service
- Admera Health - Key offerings
- SWOT
- 15.6 Agilent Technologies Inc.
- Agilent Technologies Inc. - Overview
- Agilent Technologies Inc. - Business segments
- Agilent Technologies Inc. - Key news
- Agilent Technologies Inc. - Key offerings
- Agilent Technologies Inc. - Segment focus
- SWOT
- 15.7 Bio Rad Laboratories Inc.
- Bio Rad Laboratories Inc. - Overview
- Bio Rad Laboratories Inc. - Business segments
- Bio Rad Laboratories Inc. - Key news
- Bio Rad Laboratories Inc. - Key offerings
- Bio Rad Laboratories Inc. - Segment focus
- SWOT
- 15.8 Charles River Laboratories International Inc.
- Charles River Laboratories International Inc. - Overview
- Charles River Laboratories International Inc. - Business segments
- Charles River Laboratories International Inc. - Key offerings
- Charles River Laboratories International Inc. - Segment focus
- SWOT
- 15.9 Danaher Corp.
- Danaher Corp. - Overview
- Danaher Corp. - Business segments
- Danaher Corp. - Key news
- Danaher Corp. - Key offerings
- Danaher Corp. - Segment focus
- SWOT
- 15.10 Eurofins Scientific SE
- Eurofins Scientific SE - Overview
- Eurofins Scientific SE - Business segments
- Eurofins Scientific SE - Key offerings
- Eurofins Scientific SE - Segment focus
- SWOT
- 15.11 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.12 Illumina Inc.
- Illumina Inc. - Overview
- Illumina Inc. - Business segments
- Illumina Inc. - Key news
- Illumina Inc. - Key offerings
- Illumina Inc. - Segment focus
- SWOT
- 15.13 Laboratory Corp. of America Holdings
- Laboratory Corp. of America Holdings - Overview
- Laboratory Corp. of America Holdings - Business segments
- Laboratory Corp. of America Holdings - Key news
- Laboratory Corp. of America Holdings - Key offerings
- Laboratory Corp. of America Holdings - Segment focus
- SWOT
- 15.14 Myriad Genetics Inc.
- Myriad Genetics Inc. - Overview
- Myriad Genetics Inc. - Product / Service
- Myriad Genetics Inc. - Key news
- Myriad Genetics Inc. - Key offerings
- SWOT
- 15.15 OneOme LLC
- OneOme LLC - Overview
- OneOme LLC - Product / Service
- OneOme LLC - Key offerings
- SWOT
- 15.16 QIAGEN N.V.
- QIAGEN N.V. - Overview
- QIAGEN N.V. - Product / Service
- QIAGEN N.V. - Key news
- QIAGEN N.V. - Key offerings
- SWOT
- 15.17 Regeneron Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc. - Overview
- Regeneron Pharmaceuticals Inc. - Product / Service
- Regeneron Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.18 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
